- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for Symvess and autologous vein were similar for treatment of vascular trauma - DURHAM, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, b ...

Core Insights - Humacyte, Inc. announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) has been accepted for oral presentation at the Society for Vascular Surgery Vascular Annual Meeting (VAM25) [1] - The presentation will highlight that the ATEV outperforms arteriovenous fistula in high-risk patients undergoing hemodialysis, based on results from the CLN-PRO-V007 randomized controlled trial [1][2] Company Overview - Humacyte is a biotechnology platform company focused on developing universally implantable bioengineered human tissues and advanced tissue constructs aimed at improving patient outcomes and transforming medical practices [3] - The company has received FDA approval for its Biologics License Application for the ATEV in the vascular trauma indication as of December 2024, and is conducting late-stage clinical trials for other vascular applications [3] - The ATEV has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, indicating its potential in treating various vascular conditions [3] Presentation Details - The presentation titled "Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results from the CLN-PRO-V007 Randomized Controlled Trial" will be delivered by Dr. Mohamad A. Hussain at the VAM25 meeting [2] - The session is scheduled for June 6, 2025, at 10:50 a.m. CT [2]